Core Viewpoint - The company has demonstrated accelerated revenue and profit growth in Q3 2025, with a notable improvement in cash flow and gross margin, despite some challenges in contract signing and market conditions [1][2][3]. Financial Performance - For Q1-3 2025, the company achieved revenue of 136.3 billion yuan, a year-on-year increase of 1.2%, and a net profit attributable to shareholders of 4.23 billion yuan, up 10.3% [1]. - Quarterly breakdown shows Q1, Q2, and Q3 revenues of 44.7 billion, 46.1 billion, and 45.6 billion yuan respectively, with Q3 showing a 4% year-on-year increase [1]. - Gross margin for Q1-3 was 9.43%, up 0.35 percentage points year-on-year, with Q3 showing a 0.71 percentage point increase [2]. - Operating cash flow improved significantly, with Q3 showing a net inflow of 4.5 billion yuan, an increase of 5.5 billion yuan year-on-year [2]. Contract and Market Activity - The company signed new contracts worth 284.6 billion yuan in Q1-3 2025, a slight increase of 0.2% year-on-year, with Q3 contracts totaling 78.5 billion yuan, down 3% [3]. - The domestic market showed recovery in Q3, with new contracts increasing by 18% year-on-year, while the overseas market faced a decline of 50% [3]. - A significant contract was signed during the Shanghai Cooperation Organization summit for a petrochemical project in Azerbaijan, valued at approximately 12 billion USD, indicating potential for future growth in overseas markets [3]. Industrial Projects and Future Outlook - The company is advancing multiple industrial projects, including the Tianchen Qixiang adiponitrile project operating at 85% capacity, and several other projects in stable operation [4]. - The second growth curve from industrial projects is expected to enhance the company's business structure and profitability [4]. - Forecasts for net profit attributable to shareholders for 2025-2027 are 6.4 billion, 7.3 billion, and 8.1 billion yuan respectively, with corresponding EPS of 1.05, 1.19, and 1.32 yuan [4].

证券研究报告 | 公司点评 gszqdatemark 2025 04 27 年 月 日 中国化学（601117.SH） 当前时点如何看中国化学？ 估值处于历史底部，现金流情况优异，有息债务率极低，分红具备较大提升空间。公司 当前 PB 为 0.75 倍，处于近 10 年的 6.2%分位，具备较强安全边际。公司 2024Q3 末 有息债务率仅为 6.3%（8 大建筑央企中最低），在手现金类资产 397 亿元，减去有息 债务后为 256 亿元（公司当前市值为 453 亿元），是 8 大建筑央企中唯一在手现金大于 有息负债的公司。公司自上市以来每年经营性现金流净额均为正，且近五年（2019-2023 年）经营性现金流与投资性现金流净额之和为 139 亿元（8 大建筑央企仅有中国化学与 中国中冶为正）。公司现金流及资产负债表情况实际与中钢国际、中材国际等公司特征 类似（自由现金流为正、有息债务率低、在手现金大于有息债务），相较于两家公司平 均 43%的分红率，未来公司分红率（目前 20%）具备较大潜在提升空间。 己二腈项目运行顺利，受益进口替代加速及原材料价格下行，盈利有望明显提升。公司 己二腈项目整体进展顺利，负荷 ...

证券研究报告 | 公司点评 gszqdatemark 2025 04 27 年 月 日 中国化学（601117.SH） 当前时点如何看中国化学？ 估值处于历史底部，现金流情况优异，有息债务率极低，分红具备较大提升空间。公司 当前 PB 为 0.75 倍，处于近 10 年的 6.2%分位，具备较强安全边际。公司 2024Q3 末 有息债务率仅为 6.3%（8 大建筑央企中最低），在手现金类资产 397 亿元，减去有息 债务后为 256 亿元（公司当前市值为 453 亿元），是 8 大建筑央企中唯一在手现金大于 有息负债的公司。公司自上市以来每年经营性现金流净额均为正，且近五年（2019-2023 年）经营性现金流与投资性现金流净额之和为 139 亿元（8 大建筑央企仅有中国化学与 中国中冶为正）。公司现金流及资产负债表情况实际与中钢国际、中材国际等公司特征 类似（自由现金流为正、有息债务率低、在手现金大于有息债务），相较于两家公司平 均 43%的分红率，未来公司分红率（目前 20%）具备较大潜在提升空间。 己二腈项目运行顺利，受益进口替代加速及原材料价格下行，盈利有望明显提升。公司 己二腈项目整体进展顺利，负荷 ...